- Home
- FENC vs CATX Comparison
FENC vs CATX Comparison
Compare FENC & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- CATX
- Stock Information
- Founded
- FENC 1996
- CATX 1983
- Country
- FENC United States
- CATX United States
- Employees
- FENC N/A
- CATX N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- CATX Medical/Dental Instruments
- Sector
- FENC Health Care
- CATX Health Care
- Exchange
- FENC Nasdaq
- CATX Nasdaq
- Market Cap
- FENC 156.9M
- CATX 182.9M
- IPO Year
- FENC 2001
- CATX N/A
- Fundamental
- Price
- FENC $5.95
- CATX $2.34
- Analyst Decision
- FENC Strong Buy
- CATX Strong Buy
- Analyst Count
- FENC 2
- CATX 10
- Target Price
- FENC $14.00
- CATX $13.89
- AVG Volume (30 Days)
- FENC 50.4K
- CATX 619.9K
- Earning Date
- FENC 05-20-2025
- CATX 05-12-2025
- Dividend Yield
- FENC N/A
- CATX N/A
- EPS Growth
- FENC N/A
- CATX N/A
- EPS
- FENC N/A
- CATX N/A
- Revenue
- FENC $47,538,000.00
- CATX $1,454,000.00
- Revenue This Year
- FENC $2.68
- CATX N/A
- Revenue Next Year
- FENC $71.63
- CATX N/A
- P/E Ratio
- FENC N/A
- CATX N/A
- Revenue Growth
- FENC 123.69
- CATX 1.40
- 52 Week Low
- FENC $3.96
- CATX $1.60
- 52 Week High
- FENC $10.07
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- FENC 51.33
- CATX 51.17
- Support Level
- FENC $5.85
- CATX $2.18
- Resistance Level
- FENC $6.61
- CATX $2.65
- Average True Range (ATR)
- FENC 0.36
- CATX 0.16
- MACD
- FENC 0.06
- CATX 0.02
- Stochastic Oscillator
- FENC 54.20
- CATX 56.25
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.